F S&P 500
5,512.75 +21.75 (+0.40%) F Dow Jones
38,888.00 +29.00 (+0.07%) F Nasdaq
20,040.25 +121.00 (+0.61%) E-mini Russell 2000 Index Futur
2,053.30 +4.00 (+0.20%) Petróleo
81.70 +0.13 (+0.16%) Oro
2,353.90 +7.00 (+0.30%)
Bioqual, Inc. (BIOQ)
Bioqual, Inc.
9600 Medical Center Drive
Suite 101
Rockville, MD 20850-3336
United States
240-404-7654
https://www.bioqual.com
Sector(es): Healthcare
Industria: Diagnostics & Research
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Mark G. Lewis Ph.D. | Chairman of the Board, CEO & President | N/D | N/D | 1955 |
| Mr. Charles C. Kirk Jr., CPA | Chief Financial Officer | N/D | N/D | N/D |
| Mitch Franklin | Chief Operating Officer | N/D | N/D | N/D |
| Ms. Hanne Andersen-Elyard Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
Descripción
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de Bioqual, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
